Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analysis of the CONDOR Study

A dose reduction strategy for adalimumab, etanercept and ustekinumab in patients with psoriasis who have stable and low disease activity has recently been compared with usual care in the CONDOR study (CONtrolled DOse Reduction) of biologics in patients with psoriasis with low disease activity. The a...

Descripción completa

Detalles Bibliográficos
Autores principales: ATALAY, Selma, VAN DEN REEK, Juul M. P. A., OTERO, Marisol E., NJOO, Marcellus D., MOMMERS, Johannes M., OSSENKOPPELE, Paul M., KOETSIER, Marjolein I., BERENDS, Maartje A., VAN DE KERKHOF, Peter C. M., GROENEWOUD, Hans M. M., DEN BROEDER, Alfons A., DE JONG, Elke M. G. J., KIEVIT, Wietske
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society for Publication of Acta Dermato-Venereologica 2020
Materias:
Investigative Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309701/
https://www.ncbi.nlm.nih.gov/pubmed/33196101
http://dx.doi.org/10.2340/00015555-3692

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309701/
https://www.ncbi.nlm.nih.gov/pubmed/33196101
http://dx.doi.org/10.2340/00015555-3692

Ejemplares similares